CN118019541A - 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂 - Google Patents
在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂 Download PDFInfo
- Publication number
- CN118019541A CN118019541A CN202280057232.3A CN202280057232A CN118019541A CN 118019541 A CN118019541 A CN 118019541A CN 202280057232 A CN202280057232 A CN 202280057232A CN 118019541 A CN118019541 A CN 118019541A
- Authority
- CN
- China
- Prior art keywords
- compound
- dose
- compounds
- glun
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240125P | 2021-09-02 | 2021-09-02 | |
| US63/240,125 | 2021-09-02 | ||
| PCT/US2022/042496 WO2023034589A1 (en) | 2021-09-02 | 2022-09-02 | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118019541A true CN118019541A (zh) | 2024-05-10 |
Family
ID=85412916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280057232.3A Pending CN118019541A (zh) | 2021-09-02 | 2022-09-02 | 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20240360091A1 (enExample) |
| EP (1) | EP4395783A4 (enExample) |
| JP (1) | JP2024533182A (enExample) |
| CN (1) | CN118019541A (enExample) |
| AU (1) | AU2022339672B2 (enExample) |
| CA (1) | CA3230601A1 (enExample) |
| WO (1) | WO2023034589A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025255430A1 (en) * | 2024-06-07 | 2025-12-11 | Seyltx, Inc. | Compositions and methods for treating chronic cough |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002028814A2 (en) * | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
| WO2002072542A2 (en) | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
| US20060199864A1 (en) * | 2004-08-23 | 2006-09-07 | Traynelis Stephen F | Selection of pH-dependent compounds for in vivo therapy |
| WO2006060461A1 (en) * | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| CN103058957A (zh) * | 2007-06-29 | 2013-04-24 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| CA2704475A1 (en) | 2007-11-06 | 2009-05-14 | Emory University | Methods of identifying improved nmda receptor antagonists |
| BRPI0912362A2 (pt) * | 2008-05-09 | 2015-10-06 | Univ Emory | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos |
| AU2010331949A1 (en) | 2009-12-15 | 2012-07-12 | Neurop, Inc. | Compounds for the treatment of neurologic disorders |
| WO2013170072A2 (en) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
-
2022
- 2022-09-02 CN CN202280057232.3A patent/CN118019541A/zh active Pending
- 2022-09-02 JP JP2024514040A patent/JP2024533182A/ja active Pending
- 2022-09-02 WO PCT/US2022/042496 patent/WO2023034589A1/en not_active Ceased
- 2022-09-02 AU AU2022339672A patent/AU2022339672B2/en active Active
- 2022-09-02 US US18/688,300 patent/US20240360091A1/en active Pending
- 2022-09-02 CA CA3230601A patent/CA3230601A1/en active Pending
- 2022-09-02 EP EP22865618.7A patent/EP4395783A4/en active Pending
-
2024
- 2024-07-19 US US18/778,172 patent/US12415790B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024533182A (ja) | 2024-09-12 |
| WO2023034589A1 (en) | 2023-03-09 |
| EP4395783A4 (en) | 2025-11-26 |
| US12415790B2 (en) | 2025-09-16 |
| US20240360091A1 (en) | 2024-10-31 |
| EP4395783A1 (en) | 2024-07-10 |
| AU2022339672A1 (en) | 2024-02-22 |
| US20240400528A1 (en) | 2024-12-05 |
| CA3230601A1 (en) | 2023-03-09 |
| AU2022339672B2 (en) | 2025-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11993588B2 (en) | Crystalline forms of a MAGL inhibitor | |
| JP2023153783A (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| JP6955039B2 (ja) | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 | |
| CN105163735B (zh) | 用于治疗神经退行性疾病和其他疾病的组合物和方法 | |
| EP2827711A1 (en) | APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF | |
| KR20200044790A (ko) | 중수소화 돔페리돈 조성물, 방법, 및 제조 | |
| CA3208828A1 (en) | Methods and compositions for treating agitation | |
| TW201822765A (zh) | 用sGC刺激劑治療CNS疾病 | |
| EP4480545A2 (en) | Formulations of a plasma kallikrein inhibitor | |
| US20230381162A1 (en) | Treatments of angioedema | |
| US12415790B2 (en) | GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH | |
| EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| JP2011507949A (ja) | 腎臓病を処置及び予防するための薬学的組成物 | |
| RU2799564C2 (ru) | Кристаллические формы ингибитора magl | |
| US10702537B2 (en) | Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection | |
| HK40069310A (en) | A crystalline form of a magl inhibitor | |
| US20220040222A1 (en) | Treatment for methamphetamine cardiovascular disease | |
| HK40100310A (zh) | 包含孟鲁司特或其药学上可接受的盐和左西替利嗪或其药学上可接受的盐的稳定性提高的薄膜包衣片剂 | |
| TW202510847A (zh) | 包括胍法辛的醫藥組合物及其製備方法 | |
| EA041551B1 (ru) | Кристаллические формы ингибитора magl | |
| HK40009165A (en) | A crystalline form of a magl inhibitor | |
| HK40009165B (en) | A crystalline form of a magl inhibitor | |
| HK1259508B (zh) | 氘代多潘立酮组合物和用於治疗病症的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |